These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 7658269)

  • 1. Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density.
    Saggese G; Baroncelli GI; Bertelloni S; Perri G
    J Pediatr; 1995 Sep; 127(3):395-402. PubMed ID: 7658269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency.
    Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; Di Nero G
    J Pediatr; 1993 Jan; 122(1):37-45. PubMed ID: 8419613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of recombinant human growth hormone in children with X-linked hypophosphatemia.
    Seikaly MG; Brown R; Baum M
    Pediatrics; 1997 Nov; 100(5):879-84. PubMed ID: 9346990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets.
    Baroncelli GI; Bertelloni S; Ceccarelli C; Saggese G
    J Pediatr; 2001 Feb; 138(2):236-43. PubMed ID: 11174622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. X-linked hypophosphatemia: effects of treatment with recombinant human growth hormone.
    Reusz GS; Miltényi G; Stubnya G; Szabó A; Horváth C; Byrd DJ; Péter F; Tulassay T
    Pediatr Nephrol; 1997 Oct; 11(5):573-7. PubMed ID: 9323282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A trial of growth hormone therapy in well-controlled hypophosphataemic rickets.
    Cameron FJ; Sochett EB; Daneman A; Kooh SW
    Clin Endocrinol (Oxf); 1999 May; 50(5):577-82. PubMed ID: 10468922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term influence of calcitriol (1,25-dihydroxyvitamin D) and supplemental phosphate in X-linked hypophosphatemic rickets.
    Chesney RW; Mazess RB; Rose P; Hamstra AJ; DeLuca HF; Breed AL
    Pediatrics; 1983 Apr; 71(4):559-67. PubMed ID: 6300745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Growth hormone treatment of familial hypophosphatemic rickets].
    Saggese G; Baroncelli GI; Barsanti S
    Arch Pediatr; 1998; 5 Suppl 4():360S-363S. PubMed ID: 9853084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone therapy in hypophosphatemic rickets.
    Wilson DM; Lee PD; Morris AH; Reiter EO; Gertner JM; Marcus R; Quarmby VE; Rosenfeld RG
    Am J Dis Child; 1991 Oct; 145(10):1165-70. PubMed ID: 1928011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute biochemical effects of growth hormone treatment compared with conventional treatment in familial hypophosphataemic rickets.
    Patel L; Clayton PE; Brain C; Pelekouda E; Addison GM; Price DA; Mughal MZ
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):687-96. PubMed ID: 8759181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
    Drezner MK; Lyles KW; Haussler MR; Harrelson JM
    J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant growth hormone therapy for X-linked hypophosphatemia in children.
    Huiming Y; Chaomin W
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004447. PubMed ID: 15674949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets.
    Glorieux FH; Marie PJ; Pettifor JM; Delvin EE
    N Engl J Med; 1980 Oct; 303(18):1023-31. PubMed ID: 6252463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.
    Harrell RM; Lyles KW; Harrelson JM; Friedman NE; Drezner MK
    J Clin Invest; 1985 Jun; 75(6):1858-68. PubMed ID: 3839245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth in X-linked hypophosphatemic rickets.
    Ariceta G; Langman CB
    Eur J Pediatr; 2007 Apr; 166(4):303-9. PubMed ID: 17171343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in bone mineral density, growth velocity and renal function of prepubertal uremic children during growth hormone treatment.
    Lanes R; Gunczler P; Orta N; Bosquez M; Scovino R; Dominguez L; Esaa S; Weisinger JR
    Horm Res; 1996; 46(6):263-8. PubMed ID: 8982736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children.
    Crofton PM; Stirling HF; Schönau E; Kelnar CJ
    Clin Endocrinol (Oxf); 1996 Apr; 44(4):385-94. PubMed ID: 8706304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant growth hormone therapy for X-linked hypophosphatemia in children.
    Smith S; Remmington T
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD004447. PubMed ID: 34618915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic control and growth during exclusive growth hormone treatment in X-linked hypophosphatemic rickets.
    Makitie O; Toiviainen-Salo S; Marttinen E; Kaitila I; Sochett E; Sipila I
    Horm Res; 2008; 69(4):212-20. PubMed ID: 18204268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII).
    al-Aqeel A; Ozand P; Sobki S; Sewairi W; Marx S
    Clin Endocrinol (Oxf); 1993 Aug; 39(2):229-37. PubMed ID: 8396512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.